Price (delayed)
$42
Market cap
$7.07B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.66
Enterprise value
$6.95B
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities
There are no recent dividends present for RVMD.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from and Sharadar.